Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells

Development of targeted therapies for triple-negative breast cancer (TNBC) is an unmet medical need. Cisplatin has demonstrated its promising potential for the treatment of TNBC in clinical trials; however, cisplatin treatment is associated with hypoxia that, in turn, promotes cancer stem cell (CSC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulaiman, Andrew, McGarry, Sarah, Chambers, Jason, Al-Kadi, Emil, Phan, Alexandra, Li, Li, Mediratta, Karan, Dimitroulakos, Jim, Addison, Christina, Li, Xuguang, Wang, Lisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461107/
https://www.ncbi.nlm.nih.gov/pubmed/32806648
http://dx.doi.org/10.3390/ijms21165788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461107/
https://www.ncbi.nlm.nih.gov/pubmed/32806648
http://dx.doi.org/10.3390/ijms21165788

Ejemplares similares